Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 01/20 10:01:02 pm
62.53 USD   +3.65%
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUD..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CET

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUDA® (pembroli..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
01/19 STUDIES FROM MERCK & COMPANY PROVIDE : PCSK9 as an...
01/19 MERCK : Reports Outline Pharmacology and Toxicology Study Findings from Merck & ..
01/19 MERCK : Researchers at Merck & Company Discuss Findings in Bioanalysis (Reductio..
01/19 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/19 MERCK : Recent Findings from Merck & Company Advance Knowledge in Bioanalysis (A..
01/19 MERCK : to Participate at the 35th Annual J.P. Morgan Healthcare Conference
01/19 RESEARCHERS AT MERCK & COMPANY TARGE : A Powerful...
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 SNIPPET ROUNDUP : Opdivo's First-Line Lung Combo Delay And Colucid's Lilly Windf..
01/20 ASCO-GI : Opdivo Heads Close Pack Of Anti-PD-1s In Gastric Cancer
01/20 Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees..
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/20 Why Gilead Is Undervalued
Advertisement
Financials ($)
Sales 2016 39 931 M
EBIT 2016 13 699 M
Net income 2016 5 950 M
Debt 2016 3 981 M
Yield 2016 2,97%
P/E ratio 2016 30,17
P/E ratio 2017 17,86
EV / Sales 2016 4,42x
EV / Sales 2017 4,37x
Capitalization 172 404 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,2 $
Spread / Average Target 9,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.6.22%172 404
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
SANOFI-1.66%104 532
More Results